NurExone Biologic Inc.

Biotechnology · TECHNION CITY, HAIFA, L3

BiotechnologySEC Form D

NurExone Biologic Inc. filed a Form D with the U.S. Securities and Exchange Commission on March 18, 2026, reporting $279,910 raised.

Incorporated in Ontario, Canada and based in TECHNION CITY, HAIFA, L3, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that NurExone Biologic Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Lior ShaltielExecutive Officer · Director
  • Eran OvadyaExecutive Officer
  • Yoram DruckerExecutive Officer · Director
  • Oded OrgilDirector
  • James RichardsonDirector
  • Eyal GabbaiDirector

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
May 26, 2026View SEC Form D
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
May 22, 2026View SEC Form D
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
May 22, 2026View SEC Form D
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
May 21, 2026View SEC Form D
$10.0MRaised

Senti Biosciences Holdings, Inc.

BiotechnologySouth San Francisco, CA
May 20, 2026View SEC Form D
NurExone Biologic Inc. raised $279.9K — SEC Form D